Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

BIOTRONIK launches ultra-high energy ICD for heart failure patients

BIOTRONIK has launched Inventra HF-T, the first and only implantable cardioverter defibrillator (ICD) available in the US that delivers an ultra-high energy with 42 joules (J) on the first shock.

Inventra is an ICD designed for heart failure patients known as a cardiac resynchronization therapy defibrillator (CRT-D).

For many patients suffering from tachycardia (fast arrhythmias), an ICD is necessary to convert dangerous arrhythmias to a normal heart rhythm.

ICDs provide life-saving shocks to the heart as needed. Patient anatomy and health conditions impact the heart's response to shock therapy. To save lives, it is critical for an ICD to deliver an effectively powerful shock as soon as possible.

"For an increasing number of patients – specifically those with larger cardiac anatomy and lower ejection fraction – a shock that is higher than the standard 36-37 J may be needed to convert irregular arrhythmia," said Dr. Mark Mascarenhas, electrophysiologist at Jersey Shore University Medical Center in Neptune, New Jersey.

"The sooner an effective shock can be delivered, the likelihood of survival increases for these patients. For such patients, a CRT-D that delivers ultra-high energy on the first shock has a higher chance of converting the irregular arrhythmia. With the availability of Inventra HF-T, more heart failure patients will be able to receive 42 J energy delivered upon the first shock and, hence, receive life-saving therapy."

BIOTRONIK's Inventra line of ICDs currently includes Inventra HF-T and Inventra DX. BIOTRONIK's DX system offers dual-chamber diagnostics with one specialized defibrillator lead, benefiting patients with minimized risk and expense.

"We invest significantly in research and development focused on advancements that improve patient lives and reduce risks, for the patient and the provider," said Marlou Janssen, President, BIOTRONIK, Inc.

 A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products.